WRF
ALXN

Waddell & Reed Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Waddell & Reed Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,100
Closed -$2.72M – 533
2019
Q1 		$2.72M Sell
20,100
-16,580
-45% -$2.06M 0.01% 466
2018
Q4 		$3.57M Sell
36,680
-200,005
-85% -$23.6M 0.01% 459
2018
Q3 		$32.9M Sell
236,685
-50,770
-18% -$6.37M 0.07% 279
2018
Q2 		$35.7M Sell
287,455
-596,536
-67% -$69.7M 0.08% 265
2018
Q1 		$98.5M Sell
883,991
-849,020
-49% -$101M 0.22% 115
2017
Q4 		$207M Sell
1,733,011
-363,676
-17% -$44.3M 0.46% 56
2017
Q3 		$294M Buy
2,096,687
+438,767
+26% +$59.6M 0.65% 36
2017
Q2 		$202M Sell
1,657,920
-386,146
-19% -$44.9M 0.44% 59
2017
Q1 		$248M Sell
2,044,066
-1,043,199
-34% -$134M 0.53% 53
2016
Q4 		$378M Buy
3,087,265
+622,286
+25% +$76.1M 0.83% 26
2016
Q3 		$302M Buy
2,464,979
+49,873
+2% +$6.42M 0.63% 41
2016
Q2 		$282M Sell
2,415,106
-138,046
-5% -$19.6M 0.59% 47
2016
Q1 		$355M Sell
2,553,152
-641,892
-20% -$94.2M 0.67% 39
2015
Q4 		$609M Sell
3,195,044
-261,643
-8% -$45.7M 0.99% 22
2015
Q3 		$541M Buy
3,456,687
+1,450,338
+72% +$265M 0.89% 27
2015
Q2 		$363M Buy
2,006,349
+466,222
+30% +$80.5M 0.52% 58
2015
Q1 		$267M Buy
1,540,127
+305,033
+25% +$55.2M 0.37% 78
2014
Q4 		$229M Buy
1,235,094
+90,045
+8% +$16.7M 0.32% 90
2014
Q3 		$190M Sell
1,145,049
-95,076
-8% -$15.6M 0.26% 99
2014
Q2 		$194M Sell
1,240,125
-221,820
-15% -$35M 0.28% 97
2014
Q1 		$222M Buy
1,461,945
+147,190
+11% +$23.4M 0.34% 78
2013
Q4 		$175M Buy
1,314,755
+246,339
+23% +$29.6M 0.28% 97
2013
Q3 		$124M Buy
1,068,416
+63,210
+6% +$6.94M 0.24% 113
2013
Q2 		$92.7M Buy
+1,005,206
New +$96.9M 0.19% 128

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Waddell & Reed Financial's ALXN Position: Q2 2019 in Review

Waddell & Reed Financial sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 20,100 shares — an estimated $2.72M sold.

Waddell & Reed Financial first reported a position in ALXN in Q2 2013 and held it in 24 quarters. The position peaked at $609M in Q4 2015. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • Waddell & Reed Financial reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Waddell & Reed Financial sold 20,100 Alexion Pharmaceuticals shares in Q2 2019, an estimated $2.72M.
  • Waddell & Reed Financial first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • Waddell & Reed Financial's Alexion Pharmaceuticals position peaked at $609M in Q4 2015.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Waddell & Reed Financial's 13F filing for Q2 2019, filed 14 Aug 2019.